Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
China · Delayed Price · Currency is CNY 32.81
-1.38 (-4.04%)
Jun 2, 2026, 3:00 PM CST
SHA:603590 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 917.11 | 914.24 | 824.43 | 917.75 | 851.05 | 693.03 |
Other Revenue | 0.88 | 0.88 | 0.97 | 2.26 | 15.68 | 116.76 |
| 917.99 | 915.12 | 825.4 | 920.01 | 866.73 | 809.78 | |
Revenue Growth (YoY) | 9.52% | 10.87% | -10.28% | 6.15% | 7.03% | 0.14% |
Cost of Revenue | 93.24 | 92.25 | 86.26 | 101.05 | 126.65 | 105.76 |
Gross Profit | 824.75 | 822.87 | 739.14 | 818.96 | 740.07 | 704.02 |
Selling, General & Admin | 561.15 | 567.52 | 553.76 | 583.28 | 525.88 | 479.34 |
Research & Development | 57.12 | 51.86 | 54.94 | 94.91 | 86.78 | 102.27 |
Other Operating Expenses | 10.37 | 9.04 | 6.75 | 5.64 | 6.04 | 8.69 |
Operating Expenses | 637.49 | 639.7 | 620.37 | 689.42 | 620.56 | 591.51 |
Operating Income | 187.26 | 183.17 | 118.77 | 129.54 | 119.51 | 112.51 |
Interest Expense | -7.8 | -7.53 | -6.16 | -2.78 | -0.86 | -1.41 |
Interest & Investment Income | 26.27 | 26.68 | 30.98 | 19.33 | 18.52 | 24.57 |
Currency Exchange Gain (Loss) | -3.84 | -3.84 | -1.29 | 0.5 | 0.26 | 0.31 |
Other Non Operating Income (Expenses) | -1.88 | -3.31 | -1.56 | -1.7 | -0.36 | 1.58 |
EBT Excluding Unusual Items | 200 | 195.16 | 140.74 | 144.9 | 137.06 | 137.57 |
Impairment of Goodwill | - | - | -97.64 | - | - | - |
Gain (Loss) on Sale of Investments | 4.42 | 4.18 | -0.49 | -12.78 | -7.65 | 35.64 |
Gain (Loss) on Sale of Assets | -0.61 | -0.52 | -0.03 | -0.13 | -0.01 | 0 |
Asset Writedown | -0.02 | -0.02 | -7.77 | - | -4.06 | - |
Other Unusual Items | -10.96 | -9.11 | 4.05 | -9.26 | 14.98 | 15.64 |
Pretax Income | 192.84 | 189.69 | 38.86 | 122.73 | 140.32 | 188.86 |
Income Tax Expense | 23.04 | 20.26 | 17.33 | -64.84 | 16.42 | 21.42 |
Earnings From Continuing Operations | 169.8 | 169.42 | 21.53 | 187.57 | 123.89 | 167.44 |
Minority Interest in Earnings | -1.11 | -3.46 | 20.69 | -37.12 | -22.4 | -19.46 |
Net Income | 168.68 | 165.97 | 42.22 | 150.45 | 101.49 | 147.99 |
Net Income to Common | 168.68 | 165.97 | 42.22 | 150.45 | 101.49 | 147.99 |
Net Income Growth | 274.35% | 293.13% | -71.94% | 48.24% | -31.42% | -19.29% |
Shares Outstanding (Basic) | 158 | 158 | 156 | 157 | 156 | 157 |
Shares Outstanding (Diluted) | 159 | 160 | 156 | 157 | 156 | 157 |
Shares Change (YoY) | 1.07% | 2.06% | -0.23% | 0.37% | -0.82% | -1.26% |
EPS (Basic) | 1.07 | 1.05 | 0.27 | 0.96 | 0.65 | 0.94 |
EPS (Diluted) | 1.06 | 1.04 | 0.27 | 0.96 | 0.65 | 0.94 |
EPS Growth | 270.41% | 285.19% | -71.88% | 47.69% | -30.85% | -18.26% |
Free Cash Flow | 127.91 | 62.23 | 68.22 | 98.44 | 23.38 | -108.43 |
Free Cash Flow Per Share | 0.80 | 0.39 | 0.44 | 0.63 | 0.15 | -0.69 |
Dividend Per Share | 0.350 | 0.350 | 0.600 | 0.300 | 0.200 | 0.300 |
Dividend Growth | -41.67% | -41.67% | 100.00% | 50.00% | -33.33% | -14.29% |
Gross Margin | 89.84% | 89.92% | 89.55% | 89.02% | 85.39% | 86.94% |
Operating Margin | 20.40% | 20.02% | 14.39% | 14.08% | 13.79% | 13.89% |
Profit Margin | 18.38% | 18.14% | 5.12% | 16.35% | 11.71% | 18.27% |
Free Cash Flow Margin | 13.93% | 6.80% | 8.27% | 10.70% | 2.70% | -13.39% |
EBITDA | 216.32 | 212.67 | 150.01 | 165.35 | 151.54 | 144.29 |
EBITDA Margin | 23.57% | 23.24% | 18.17% | 17.97% | 17.48% | 17.82% |
D&A For EBITDA | 29.06 | 29.5 | 31.24 | 35.8 | 32.03 | 31.78 |
EBIT | 187.26 | 183.17 | 118.77 | 129.54 | 119.51 | 112.51 |
EBIT Margin | 20.40% | 20.02% | 14.39% | 14.08% | 13.79% | 13.89% |
Effective Tax Rate | 11.95% | 10.68% | 44.60% | - | 11.70% | 11.34% |
Revenue as Reported | 917.99 | 915.12 | 825.4 | 920.01 | 866.73 | 809.78 |
Advertising Expenses | - | - | - | - | 32.55 | 350.29 |